AstraZeneca to present the latest cardiovascular research
Stroke is a major cause of disability and death worldwide and the third most common cause of death in developed countries. Nearly six million people die from stroke every year and another five million are left permanently disabled.
While many of the hopes and disappointments for AZ’s business are around oncology, it still needs its cardiovascular and diabetes portfolio to perform.
Novartis to discuss canakinumab results with regulators.
Companies awaiting CV outcomes trial, and court decision in patent case
Italian pharma gets EU rights to Seloken.
Merck and Pfizer have Boehringer and Lilly in their sights with ertugliflozin